3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
58
Small Cell Lung Carcinoma
22
Carcinoma, Hepatocellular
17
Neoplasms
15
Lung Neoplasms
14
Biliary Tract Neoplasms
12
Neoplasm Metastasis
11
Breast Neoplasms
11
Recurrence
10
Squamous Cell Carcinoma of Head and Neck
9
Melanoma
9
Carcinoma
9
Advanced Solid Tumors
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Liver Neoplasms
7
Head and Neck Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Carcinoma, Renal Cell
6
Prostatic Neoplasms
5
Lymphoma
5
Uterine Cervical Neoplasms
4
Neoplasms by Site
4
Multiple Myeloma
4
Lymphoma, Follicular
4
Colorectal Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
3
osimertinib
3
Erlotinib Hydrochloride
3
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Gemcitabine
2
Gefitinib
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
entinostat
1
cobimetinib
1
ceralasertib
1
alectinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
AZD3759
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Respiratory Tract Diseases
×
durvalumab
×
Clear all
NCT06606847
2026-05-15
LADOGA
AstraZeneca
Phase 2
Active not recruiting
30 enrolled
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled